<DOC>
	<DOCNO>NCT01882764</DOCNO>
	<brief_summary>A study 8 week open label phase study follow year long placebo control maintenance phase subject active mild moderate ulcerative colitis ( UC ) , modify Mayo Score 4-10 endoscopy subscore 2-3 , take mesalamine ( equivalent ) concomitant medication . Subjects require clinical remission clinical response enter year long maintenance phase . This study help evaluate HMPL-004 effective subject maintain clinical remission follow successful induction therapy achieve clinical remission clinical response .</brief_summary>
	<brief_title>A Phase III Maintenance Placebo Controlled Maintenance Trial Of HMPL-004 Subjects With Mild Moderate Ulcerative Colitis</brief_title>
	<detailed_description>A two-phase multi-center study open label 8-week induction phase randomize , double-blind , placebo control maintenance phase evaluate efficacy safety HMPL-004 52-week maintenance therapy adult mild moderate UC demonstrate sub-optimal response mesalamine treatment . The study participant consist subject complete either HMPL-004-03 HMPL-004-05 induction study , complement enrollment additional subject open label induction phase meet entry criterion study . . Subjects enter maintenance study one HMPL-004 induction study modify Mayo baseline score study baseline score study . All subject enrol open label induction phase study re-evaluated clinical response remission 8-week open label 2400 mg HMPL-004 treatment period . Clinical responder remitters randomize 2:1 ( HMPL-004 : placebo ) HMPL-004 1800 mg/day placebo group 52-week maintenance phase study .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>1 . Completion induction study HMPL00403 HMPL00405 achieve clinical remission response disruption study treatment transition HMPL00404 , , open label induction phase study : active mild moderate Ulcerative Colitis define modify Mayo Score 4 10 endoscopy score activity 23 point confirm full colonoscopy within 2 week prior study . 2 . Subjects must currently receive mesalamine ≥ 2.4 g/day ( equivalent ) least 6 week prior randomization stable dosage least 2 week prior enter screen phase study ensure stable dose establish least 2 week prior endoscopic procedure . 3 . Have adequate renal , hepatic bone marrow function ( see exclusion criterion ) . 4 . Age ≥ 18 year 5 . All fertile male female subject must agree use one follow type contraception : intrauterine device , implantable progesterone device , progesterone intramuscular injection , oral contraceptive start least one month prior visit one continue duration trial , contraceptive patch , condom spermicide . 6 . Show evidence personally sign date informed consent document indicate subject ( legally acceptable representative ) inform pertinent aspect trial . 1 . Subjects intolerance mesalamine ( equivalent medication ) . 2 . Diagnosed Crohn 's disease lesion fistulas granulomas biopsy note either history baseline endoscope , would suspicious Crohn 's disease , diagnosis indeterminate colitis . 3 . Severe disease Ulcerative Colitis modify Mayo Clinic score 10 point baseline . 4 . Positive stool test pathogen sample take within 2 week prior study entry . 5 . Active clostridium difficile ( C. diff ) infection . 6 . Use Inflammatory Bowel Disease relate herbal supplement include supplement contain andrographis use probiotic two week prior study entry study . 7 . Toxic megacolon toxic colitis . 8 . Probable requirement intestinal surgery within 12 week start investigational product . 9 . Receiving oral rectal steroid within 1 month prior study entry . 10 . Receiving rectal mesalamine within 1 week prior study entry . 11 . Receiving azathioprine , 6mercaptopurine , methotrexate , tacrolimus , cyclosporine , immunosuppressive therapy time screen within precede 6 week . 12 . Receiving antiTNFα agent infliximab , adalimumab , golimumab , certolizumab pegol time screen within precede 8 week . 13 . Receiving investigational drug biologics within 1 month five halflives , whichever longer . 14 . Receiving antibiotic within 2 week study entry . 15 . Hemoglobin concentration &lt; 9 g/dl . 16 . WBC 3,000/cm3 , platelet 100,000/cm3 . 17 . Alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , and/or alkaline phosphatase &gt; 2.5 upper limit normal . 18 . Serum creatinine &gt; 1.5 time upper limit normal . 19 . Significant concurrent medical disease include : active peptic ulcer disease ; uncompensated congestive heart disease ; myocardial infarction within last 12 month ; unstable angina pectoris ; uncontrolled hypertension ; pulmonary disease require oxygen therapy . 20 . Chronic Hepatitis B history Hepatitis C. 21 . Previous colonic surgery except simple polypectomy . 22 . History cancer within last 5 year resect cutaneous basal squamous cell carcinoma , and/or situ cervical cancer . 23 . Subjects history concurrent colonic dysplasia associate UC , except completely excise sporadic colorectal polyp . 24 . Women pregnant breast feeding . 25 . Subjects know seropositive HIV , AIDS define illness , know immunodeficiency disorder . 26 . History alcohol drug abuse would interfere ability compliant study procedure . 27 . Known allergy plant Acanthaceae family . 28 . Unwillingness participate study . 29 . Any underlying medical condition Investigator 's opinion make administration study drug hazardous subject would obscure interpretation Adverse Events .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>